{"disease":{"id":"neuroendocrine-carcinomas-nec","name":"neuroendocrine carcinomas nec"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06893783","title":"Efficacy and Safety Evaluation of Tarlatamab in Advanced Extrapulmonary Neuroendocrine Carcinoma Patients","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"Inkeun Park","has_results":false},{"nct_id":"NCT05714722","title":"Epiction of the Genomic and Genetic Landscape Identifies CCL5 as a Protective Factor in Colorectal Neuroendocrine Carcinoma","phase":"","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"Zhejiang University","has_results":false},{"nct_id":"NCT07014540","title":"A Irinotecan Liposome Trial of in Advanced Neuroendocrine Carcinoma","phase":"PHASE4","overall_status":"NOT_YET_RECRUITING","enrollment_count":45,"lead_sponsor_name":"Beijing GoBroad Hospital","has_results":false},{"nct_id":"NCT04525638","title":"A Clinical Study to Assess the Combination of Two Drugs (177Lu-DOTATATE and Nivolumab) in Neuroendocrine Tumours","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":30,"lead_sponsor_name":"Fundación de investigación HM","has_results":false}],"total":4},"guidelines":[],"source":"Drug Landscape verified database"}